The Genetics of Melanoma

The Pigmentary System: Physiology and Pathophysiology: Second Edition

Volumn , Issue , 2007, Pages 472-488

  Gray Schopfer, Vanessa C ^a   Bennett, Dorothy C ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Apoptosis; Genetics; Melanocortin 1 receptor; Phosphatase and tensin homolog; Retinoblastoma

Indexed keywords

EID: 84889617701     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987100.ch24     Document Type: Chapter

References (169)

1. Adjei, A. A. Blocking oncogenic Ras signaling for cancer therapy. J. Natl. Cancer Inst. 93:1062-1074, 2001.
2. Albino, A. P., D. M. Nanus, I. R. Mentle, C. Cordon-Cardo, N. S. McNutt, J. Bressler, and M. Andreeff. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene 4:1363-1374, 1989.
3. Albino, A. P., M. J. Vidal, N. S. McNutt, C. R. Shea, V. G. Prieto, D. M. Nanus, J. M. Palmer, and N. K. Hayward. Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res. 4:35-45, 1994.
4. Arita, Y., F. Santiago-Schwarz, and D. L. Coppock. Survival mechanisms induced by 12-O-tetradecanoylphorbol-13-acetate in normal human melanocytes include inhibition of apoptosis and increased Bcl-2 expression. Melanoma Res. 10:412-420, 2000.
5. Baldi, A., D. Santini, P. Russo, C. Catricala, A. Amantea, M. Picardo, F. Tatangelo, G. Botti, E. Dragonetti, R. Murace, G. Tonini, P. G. Natali, F. Baldi, and M. G. Paggi. Analysis of APAF-1 expression in human cutaneous melanoma progression. Exp. Dermatol. 13:93-97, 2004.
6. Bar-Eli, M. Role of AP-2 in tumor growth and metastasis of human melanoma. Cancer Metastasis Rev. 18:377-385, 1999.
7. Bar-Eli, M. Gene regulation in melanoma progression by the AP-2 transcription factor. Pigment Cell Res. 14:78-85, 2001.
8. Bartkova, J., J. Lukas, P. Guldberg, J. Alsner, A. F. Kirkin, J. Zeuthen, and J. Bartek. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res. 56:5475-5483, 1996.
9. Bastiaens, M., J. ter Huurne, N. Gruis, W. Bergman, R. Westendorp, B. J. Vermeer, and J. N. Bouwes Bavinck. The melanocortin-1-receptor gene is the major freckle gene. Hum. Mol. Genet. 10:1701-1708, 2001.
10. Bastian, B. C. The longer your telomeres, the larger your nevus? Am. J. Dermatopathol. 25:83-84, 2003.
11. Bates, S., A. C. Phillips, P. A. Clark, F. Stott, G. Peters, R. L. Ludwig, and K. H. Vousden. p14ARF links the tumour suppressors RB and p53. Nature 395:124-125, 1998.
12. Bauer, J., and C. Garbe. Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data. Pigment Cell Res. 16:297-306, 2003.
13. Bell, D. W., J. M. Varley, T. E. Szydlo, D. H. Kang, D. C. Wahrer, K. E. Shannon, M. Lubratovich, S. J. Verselis, K. J. Isselbacher, J.F. Fraumeni, J. M. Birch, F. P. Li, J. E. Garber, and D. A. Haber. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286:2528-2531, 1999.
14. Bennett, D. C. Human melanocyte senescence and melanoma susceptibility genes. Oncogene 22:3063-3069, 2003.
15. Bennett, D. C., and E. E. Medrano. Molecular regulation of melanocyte senescence. Pigment Cell Res. 15:242-250, 2002.
16. Berking, C., R. Takemoto, K. Satyamoorthy, T. Shirakawa, M. Eskandarpour, J. Hansson, P. A. VanBelle, D. E. Elder, and M. Herlyn. Induction of melanoma phenotypes in human skin by growth factors and ultraviolet B. Cancer Res. 64:807-811, 2004.
17. Bishop, D. T., F. Demenais, A. M. Goldstein, W. Bergman, J. N. Bishop, B. Bressac-de Paillerets, A. Chompret, P. Ghiorzo, N. Gruis, J. Hansson, M. Harland, N. Hayward, E. A. Holland, G. J. Mann, M. Mantelli, D. Nancarrow, A. Platz, and M. A. Tucker. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J. Natl. Cancer Inst. 94:894-903, 2002.
18. Blume-Jensen, P., and T. Hunter. Oncogenic kinase signalling. Nature 411:355-365, 2001.
19. Borner, C., W. H. Schlagbauer, I. Fellay, E. Selzer, P. Polterauer, and B. Jansen. Mutated N-ras upregulates Bcl-2 in human melanoma in vitro and in SCID mice. Melanoma Res. 9:347-350, 1999.
20. Box, N. F., D. L. Duffy, W. Chen, M. Stark, N. G. Martin, R. A. Sturm, and N. K. Hayward. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am. J. Hum. Genet. 69:765-773, 2001.
21. Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J. Natl. Cancer Inst. 91:1310-1316, 1999.
22. Brookes, S., J. Rowe, M. Ruas, S. Llanos, P. A. Clark, M. Lomax, M. C. James, R. Vatcheva, S. Bates, K. H. Vousden, D. Parry, N. Gruis, N. Smit, W. Bergman, and G. Peters. INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence. EMBO J. 21:2936-2945, 2002.
23. Bush, J. A., and G. Li. The role of Bcl-2 family members in the progression of cutaneous melanoma. Clin. Exp. Metastasis 20:531-539, 2003.
24. Carey, W. P., C. J. Thompson, M. Synnestvedt, D. Guerry, A. Halpern, D. Schultz, and D. E. Elder. Dysplastic nevi as a melanoma risk factor in patients with familial melanoma. Cancer 74:3118-3125, 1994.
25. Cascorbi, I. Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication. Eur. J. Clin. Invest. 33 Suppl. 2:17-22, 2003.
26. Castellano, M., and G. Parmiani. Genes involved in melanoma: an overview of INK4a and other loci. Melanoma Res. 9:421-432, 1999.
27. Chen, D., W. Xu, E. Bales, C. Colmenares, M. Conacci-Sorrell, S. Ishii, E. Stavnezer, J. Campisi, D. E. Fisher, A. Ben Ze'ev, and E. E. Medrano. SKI activates Wnt/beta-catenin signaling in human melanoma. Cancer Res. 63:6626-6634, 2003.
28. Chin, L., J. Pomerantz, D. Polsky, M. Jacobson, C. Cohen, C. Cordon-Cardo, J. W. Horner, and R. A. DePinho. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev. 11:2822-2834, 1997.
29. Clark, W. H., D. E. Elder, D. Guerry, M. N. Epstein, M. H. Greeve, and M. Van Horn. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum. Pathol. 15:1147-1165, 1984.
30. Clark, W. H., D. E. Elder, D. Guerry, L. E. Braitman, B. J. Trock, D. Schultz, M. Synnestvedt, and A. C. Halpern. Model predicting survival in stage I melanoma based on tumor progression. J. Natl. Cancer Inst. 81:1893-1904, 1989.
31. Cook, P. J., R. Doll, and S. A. Fellingham. A mathematical model for the age distribution of cancer in man. Int. J. Cancer 4:93-112, 1969.
32. Crotty, K., S. McCarthy, and M. C. Mihm. The histological diagnosis and classification of melanoma. In: Textbook of Melanoma, J. F. Thompson, D. L. Morton, and B. B. R. Kroon (eds). New York: Martin Dunitz, 2004, pp. 115-121.
33. d'Adda di Fagagna, F., P. M. Reaper, L. Clay-Farrace, H. Fiegler, P. Carr, T. Von Zglinicki, G. Saretzki, N. P. Carter, and S. P. Jackson. A DNA damage checkpoint response in telomere-initiated senescence. Nature 426:194-198, 2003.
34. Davies, H., G. R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague, H. Woffendin, M. J. Garnett, W. Bottomley, N. Davis, E. Dicks, R. Ewing, Y. Floyd, K. Gray, S. Hall, R. Hawes, J. Hughes, V. Kosmidou, A. Menzies, C. Mould, A. Parker, C. Stevens, S. Watt, S. Hooper, R. Wilson, H. Jayatilake, B. A. Gusterson, C. Cooper, J. Shipley, D. Hargrave, K. Pritchard-Jones, N. Maitland, G. Chenevix-Trench, G. J. Riggins, D. D. Bigner, G. Palmieri, A. Cossu, A. Flanagan, A. Nicholson, J. W. Ho, S. Y. Leung, S. T. Yuen, B. L. Weber, H. F. Seigler, T. L. Darrow, H. Paterson, R. Marais, C. J. Marshall, R. Wooster, M. R. Stratton, and P. A. Futreal. Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002.
35. Davis, N. C., H. M. Shaw, and W. H. McCarthy. Melanoma: an historical perspective. In: Textbook of Melanoma, J. F. Thompson, D. L. Morton and B. B. R. Kroon (eds). New York: Martin Dunitz, 2004, pp. 1-12.
36. Demunter, A., M. Stas, H. Degreef, C. Wolf-Peeters, and J. J. van den Oord. Analysis of N-and K-ras mutations in the distinctive tumor progression phases of melanoma. J. Invest. Dermatol. 117: 1483-1489, 2001.
37. Dong, J., R. G. Phelps, R. Qiao, S. Yao, O. Benard, Z. Ronai, and S. A. Aaronson. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res. 63:3883-3885, 2003.
38. Draper, G. J., B. M. Sanders, and J. E. Kingston. Second primary neoplasms in patients with retinoblastoma. Br. J. Cancer 53:661-671, 1986.
39. Drayton, S., J. Rowe, R. Jones, R. Vatcheva, D. Cuthbert-Heavens, J. Marshall, M. Fried, and G. Peters. Tumor suppressor p161NK4a determines sensitivity of human cells to transformation by cooperating cellular oncogenes. Cancer Cell 4:301-310, 2003.
40. Dulon, M., M. Weichenthal, M. Blettner, M. Breitbart, M. Hetzer, R. Greinert, C. Baumgardt-Elms, and E. W. Breitbart. Sun exposure and number of nevi in 5-to 6-year-old European children. J. Clin. Epidemiol. 55:1075-1081, 2002.
41. Easty, D. J., and D. C. Bennett. Protein tyrosine kinases in malignant melanoma. Melanoma Res. 10:401-411, 2000.
42. Elwood, J. M. Melanoma and sun exposure. Semin. Oncol. 23: 650-666, 1996.
43. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell 78:539-542, 1994.
44. Fountain, J. W., M. Karayiorgou, M. S. Ernstoff, J. M. Kirkwood, D. R. Vlock, L. Titus-Ernstoff, B. Bouchard, S. Vijayasaradhi, A. N. Houghton, J. Lahti, V. J. Kidd, D. E. Housman, and N. C. Dracopoli. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc. Natl. Acad. Sci. USA 89:10557-10561, 1992.
45. Furukawa, Y., N. Nishimura, Y. Furukawa, M. Satoh, H. Endo, S. Iwase, H. Yamada, M. Matsuda, Y. Kano, and M. Nakamura. Apaf-1 is a mediator of E2F-1-induced apoptosis. J. Biol. Chem. 277:39760-39768, 2002.
46. Garland, C. F., F. C. Garland, and E. D. Gorham. Epidemiologic evidence for different roles of ultraviolet A and B radiation in melanoma mortality rates. Ann. Epidemiol. 13:395-404, 2003.
47. Gillanders, E., S. H. Juo, E. A. Holland, M. Jones, D. Nancarrow, D. Freas-Lutz, R. Sood, N. Park, M. Faruque, C. Markey, R. F. Kefford, J. Palmer, W. Bergman, D. T. Bishop, M. A. Tucker, B. Bressac-de Paillerets, J. Hansson, M. Stark, N. Gruis, J. N. Bishop, A. M. Goldstein, J. E. Bailey-Wilson, G. J. Mann, N. Hayward, and J. Trent. Localization of a novel melanoma susceptibility locus to 1p22. Am. J. Hum. Genet. 73:301-313, 2003.
48. Glaessl, A., A. K. Bosserhoff, R. Buettner, U. Hohenleutner, M. Landthaler, and W. Stolz. Increase in telomerase activity during progression of melanocytic cells from melanocytic naevi to malignant melanomas. Arch. Dermatol. Res. 291:81-87, 1999.
49. Gonzalgo, M. L., C. M. Bender, E. H. You, J. M. Glendening, J. F. Flores, G. J. Walker, N. K. Hayward, P. A. Jones, and J. W. Fountain. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. Cancer Res. 57:5336-5347, 1997.
50. Gruis, N. A., P. A. van der Velden, L. A. Sandkuijl, D. E. Prins, J. Weaver-Feldhaus, A. Kamb, W. Bergman, and R. R. Frants. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nature Genet. 10:351-353, 1995.
51. Guldberg, P., S. P. Thor, A. Birck, V. Ahrenkiel, A. F. Kirkin, and J. Zeuthen. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 57:3660-3663, 1997.
52. Halaban, R. Melanoma cell autonomous growth: the Rb/E2F pathway. Cancer Metastasis Rev. 18:333-343, 1999.
53. Harland, M., S. Mistry, D. T. Bishop, and J. A. Bishop. A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees. Hum. Mol. Genet. 10:2679-2686, 2001.
54. Hayward, N. New developments in melanoma genetics. Curr. Oncol. Rep. 2:300-306, 2000.
55. Hayward, N. K. Genetics of melanoma predisposition. Oncogene 22:3053-3062, 2003.
56. Hewitt, C., W. C. Lee, G. Evans, A. Howell, R. G. Elles, R. Jordan, P. Sloan, A. P. Read, and N. Thakker. Germline mutation of ARF in a melanoma kindred. Hum. Mol. Genet. 11:1273-1279, 2002.
57. Hisada, M., J. E. Garber, C. Y. Fung, J. F. Fraumeni, Jr., and F. P. Li. Multiple primary cancers in families with Li-Fraumeni syndrome. J. Natl. Cancer Inst. 90:606-611, 1998.
58. Hsieh, J. K., F. S. G. Chan, D. J. O'Connor, S. Mittnacht, S. Zhong, and X. Lu. RB regulates the stability and the apoptotic function of p53 via MDM2. Mol. Cell 3:181-193, 1999.
59. Hsu, M., T. Andl, G. Li, J. L. Meinkoth, and M. Herlyn. Cadherin repertoire determines partner-specific gap junctional communication during melanoma progression. J. Cell Sci. 113(Pt 9): 1535-1542, 2000.
60. Huang, S., M. Luca, M. Gutman, D. J. McConkey, K. E. Langley, S. D. Lyman, and M. Bar-Eli. Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene 13:2339-2347, 1996.
61. INK4a confer resistance to Ras-and Ets-induced senescence in human diploid fibroblasts. Mol. Cell. Biol. 22:8135-8143, 2002.
62. Hussussian, C. J., J. P. Struewing, A. M. Goldstein, P. A. T. Higgins, D. S. Ally, M. D. Sheahan, W. H. Clark, M. A. Tucker, and N. C. Dracopoli. Germline p16 mutations in familial melanoma. Nature Genet. 8:15-21, 1994.
63. Hutchinson, P. E., J. E. Osborne, J. T. Lear, A. G. Smith, P. W. Bowers, P. N. Morris, P. W. Jones, C. York, R. C. Strange, and A. A. Fryer. Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin. Cancer Res. 6:498-504, 2000.
64. Hwang, P. H., H. K. Yi, D. S. Kim, S. Y. Nam, J. S. Kim, and D. Y. Lee. Suppression of tumorigenicity and metastasis in B16F10 cells by PTEN/MMAC1/TEP1 gene. Cancer Lett. 172:83-91, 2001.
65. Itahana, K., Y. Zou, Y. Itahana, J. L. Martinez, C. Beausejour, J. J. Jacobs, M. van Lohuizen, V. Band, J. Campisi, and G. P. Dimri. Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1. Mol. Cell. Biol. 23:389-401, 2003.
66. Jacobs, J. J. L., K. Kleboom, S. Marino, R. A. DePinho, and M. van Lohuizen. The oncogene and Polycomb group gene bmi-1 regulates cell proliferation and senescence through the Ink4a locus. Nature 397:164-168, 1999.
67. Jafari, M., T. Papp, S. Kirchner, U. Diener, D. Henschler, G. Burg, and D. Schiffmann. Analysis of ras mutations in human melanocytic lesions: activation of the ras gene seems to be associated with the nodular type of human malignant melanoma. J. Cancer Res. Clin. Oncol. 121:23-30, 1995.
68. Jahroudi, N., and J. S. Greenberger. The role of endothelial cells in tumor invasion and metastasis. J. Neurooncol. 23:99-108, 1995.
69. Jhappan, C., F. P. Noonan, and G. Merlino. Ultraviolet radiation and cutaneous malignant melanoma. Oncogene 22:3099-3112, 2003.
70. Jiveskog, S., B. Ragnarsson-Olding, A. Platz, and U. Ringborg. N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J. Invest. Dermatol. 111:757-761, 1998.
71. Joshi, P. C., C. Carraro, and M. A. Pathak. Involvement of reactive oxygen species in the oxidation of tyrosine and dopa to melanin and in skin tanning. Biochem. Biophys. Res. Commun. 142:265-274, 1987.
72. Kamb, A., D. Shattuck-Eidens, R. Eeles, Q. Liu, N. A. Gruis, W. Ding, C. Hussey, T. Tran, Y. Miki, J. Weaver-Feldhaus, M. McClure, J. F. Aitken, D. E. Anderson, W. Bergman, R. Frants, D. E. Goldgar, A. Green, R. MacLennan, N. G. Martin, L. J. Meyer, P. Youl, J. J. Zone, M. H. Skolnick, and L. A. Cannon-Albright. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet. 8:22-26, 1994.
73. ARF. Cell 91:649-659, 1997.
74. Kanetsky, P. A., R. Holmes, A. Walker, D. Najarian, J. Swoyer, D. Guerry, A. Halpern, and T. R. Rebbeck. Interaction of glutathione S-transferase M1 and T1 genotypes and malignant melanoma. Cancer Epidemiol. Biomarkers Prev. 10:509-513, 2001.
75. Kefford, R. F., G. J. Mann, and J. Newton Bishop. Genetic predisposition to melanoma. In: Textbook of Melanoma, J. F. Thompson, D. L. Morton, and B. B. R. Kroon (eds). New York: Martin Dunitz, 2004, pp. 56-64.
76. INK4 in benign and malignant melanocytic lesions. J. Invest. Dermatol. 110:932-938, 1998.
77. Kennedy, C., J. ter Huurne, M. Berkhout, N. Gruis, M. Bastiaens, W. Bergman, R. Willemze, and J. N. Bavinck. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J. Invest. Dermatol. 117:294-300, 2001.
78. Koh, H. K. Cutaneous melanoma. N. Engl. J. Med. 325:171-182, 1991.
79. Ink4a confers susceptibility to metastatic melanoma in mice. Nature 413:83-86, 2001.
80. Kumar, R., I. Sauroja, K. Punnonen, C. Jansen, and K. Hemminki. Selective deletion of exon 1 beta of the p19ARF gene in metastatic melanoma cell lines. Genes Chrom. Cancer 23:273-277, 1998.
81. Lafuente, A., R. Molina, J. Palou, T. Castel, A. Moral, and M. Trias. Phenotype of glutathione S-transferase Mu (GSTM1) and susceptibility to malignant melanoma. MMM group. Multidisciplinary Malignant Melanoma Group. Br. J. Cancer 72:324-326, 1995.
82. Lang, J., M. Boxer, and R. MacKie. Absence of exon 15 BRAF germline mutations in familial melanoma. Hum. Mutat. 21:327-330, 2003.
83. Langley, R. G. B., R. L. Barnhill, M. C. Mihm, T. B. Fitzpatrick, and A. J. Sober. Neoplasms: cutaneous melanoma. In: Fitzpatrick's Dermatology in General Medicine, I. M. Freedberg, A. Z. Eisen, K. Wolff, K. F. Austen, L. A. Goldsmith, and S. I. Katz (eds). New York: McGraw-Hill, 2003, pp. 917-947.
84. Laud, K., C. Kannengiesser, M.-F. Avril, A. Chompret, D. Stoppa-Lyonnet, L. Desjardins, A. Eychene, F. Demenais, G. M. Lenoir, and B. Bressac-de Paillerets. BRAF as a melanoma susceptibility candidate gene? Cancer Res. 63:3061-3065, 2003.
85. Li, G., L. Tang, X. Zhou, V. Tron, and V. Ho. Chemotherapy-induced apoptosis in melanoma cells is p53 dependent. Melanoma Res. 8:17-23, 1998.
86. Li, G., K. Satyamoorthy, and M. Herlyn. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res. 61:3819-3825, 2001.
87. Liggett, W. H., and D. Sidransky. Role of the p16 tumor suppressor gene in cancer. J. Clin. Oncol. 16:1197-1206, 1998.
88. Liu, L., D. Dilworth, L. Gao, J. Monzon, A. Summers, N. Lassam, and D. Hogg. Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma. Nature Genet. 21:128-132, 1999.
89. Londono-Vallejo, J. A., H. Der-Sarkissian, L. Cazes, S. Bacchetti, and R. R. Reddel. Alternative lengthening of telomeres is characterized by high rates of telomeric exchange. Cancer Res. 64:2324-2327, 2004.
90. Maehama, T., and J. E. Dixon. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273: 13375-13378, 1998.
91. Maldonado, J. L., J. Fridlyand, H. Patel, A. N. Jain, K. Busam, T. Kageshita, T. Ono, D. G. Albertson, D. Pinkel, and B. C. Bastian. Determinants of BRAF mutations in primary melanomas. J. Natl. Cancer Inst. 95:1878-1890, 2003.
92. Meyer, P., C. Sergi, and C. Garbe. Polymorphisms of the BRAF gene predispose males to malignant melanoma. J. Carcinog. 2:7, 2003 a.
93. Meyer, P., R. Klaes, C. Schmitt, M. B. Boettger, and C. Garbe. Exclusion of BRAFV599E as a melanoma susceptibility mutation. Int. J. Cancer 106:78-80, 2003 b.
94. Momand, J., H. H. Wu, and G. Dasgupta. MDM2-master regulator of the p53 tumor suppressor protein. Gene 242:15-29, 2000.
95. Mooi, W. J., and D. S. Peeper. Pathogenesis of melanocytic naevi: growth arrest linked with cellular senescence? Histopathology 41(Suppl. 2): 120-146, 2002.
96. Mooney, E. E., J. M. Ruis Peris, A. O'Neill, and E. C. Sweeney. Apop-totic and mitotic indices in malignant melanoma and basal cell carcinoma. J. Clin. Pathol. 48:242-244, 1995.
97. Moroni, M. C., E. S. Hickman, E. L. Denchi, G. Caprara, E. Colli, F. Cecconi, H. Muller, and K. Helin. Apaf-1 is a transcriptional target for E2F and p53. Nature Cell Biol. 3:552-558, 2001.
98. Natali, P. G., M. R. Nicotra, A. B. Winkler, R. Cavaliere, A. Bigotti, and A. Ullrich. Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int. J. Cancer 52:197-201, 1992.
99. Newton, J. A., V. Bataille, K. Griffiths, J. M. Squire, P. Sasieni, J. Cuzick, D. T. Bishop, and A. Swerdlow. How common is the atypical mole syndrome phenotype in apparently sporadic melanoma? J. Am. Acad. Dermatol. 29:989-996, 1993.
100. Nishimura, E. K., H. Yoshida, T. Kunisada, and S. I. Nishikawa. Regulation of E-and P-cadherin expression correlated with melanocyte migration and diversification. Dev. Biol. 215:155-166, 1999.
101. Noonan, F. P., J. A. Recio, H. Takayama, P. Duray, M. R. Anver, W. L. Rush, E. C. De Fabo, and G. Merlino. Neonatal sunburn and melanoma in mice. Nature 413:271-272, 2001.
102. Omholt, K., A. Platz, U. Ringborg, and J. Hansson. Cytoplasmic and nuclear accumulation of beta-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma. Int. J. Cancer 92:839-842, 2001.
103. Omholt, K., A. Platz, L. Kanter, U. Ringborg, and J. Hansson. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin. Cancer Res. 9:6483-6488, 2003.
104. Palmer, J. S., D. L. Duffy, N. F. Box, J. F. Aitken, L. E. O'Gorman, A. C. Green, N. K. Hayward, N. G. Martin, and R. A. Sturm. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am. J. Hum. Genet. 66:176-186, 2000.
105. Papp, T., H. Pemsel, R. Zimmermann, R. Bastrop, D. G. Weiss, and D. Schiffmann. Mutational analysis of the N-ras, p53, p161NK4a, CDK4, and MC1R genes in human congenital melanocytic naevi. J. Med. Genet. 36:610-614, 1999.
106. Papp, T., H. Pemsel, I. Rollwitz, H. Schipper, D. G. Weiss, D. Schiffmann, and R. Zimmermann. Mutational analysis of N-ras, p53, CDKN2A (p16(INK4a)), p14(ARF), CDK4, and MC1R genes in human dysplastic melanocytic naevi. J. Med. Genet. 40:E14, 2003.
107. Park, W. S., A. O. Vortmeyer, S. Pack, P. H. Duray, R. Boni, A. A. Guerami, M. R. Emmert-Buck, L. A. Liotta, and Z. Zhuang. Allelic deletion at chromosome 9p21(p16) and 17p13(p53) in microdissected sporadic dysplastic nevus. Hum. Pathol. 29:127-130, 1998.
108. Pavey, S., T. Russell, and B. Gabrielli. G2 phase cell cycle arrest in human skin following UV irradiation. Oncogene 20:6103-6110, 2001.
109. Pavey, S. J., M. C. Cummings, D. C. Whiteman, M. Castellano, M. D. Walsh, B. G. Gabrielli, A. Green, and N. K. Hayward. Loss of p16 expression is associated with histological features of melanoma invasion. Melanoma Res. 12:539-547, 2002.
110. Pierceall, W. E., M. L. Kripke, and H. N. Ananthaswamy. N-ras mutation in ultraviolet radiation-induced murine skin cancers. Cancer Res. 52:3946-3951, 1992.
111. Plettenberg, A., C. Ballaun, J. Pammer, M. Mildner, D. Strunk, W. Weninger, and E. Tschachler. Human melanocytes and melanoma cells constitutively express the Bcl-2 proto-oncogene in situ and in cell culture. Am. J. Pathol. 146:651-659, 1995.
112. Poetsch, M., T. Dittberner, and C. Woenckhaus. PTEN/MMAC1 in malignant melanoma and its importance for tumor progression. Cancer Genet. Cytogenet. 125:21-26, 2001.
113. Pollock, P. M., and J. M. Trent. The genetics of cutaneous melanoma. Clin. Lab. Med. 20:667-690, 2000.
114. Pollock, P. M., G. J. Walker, J. M. Glendening, N. T. Que, N. C. Bloch, J. W. Fountain, and N. K. Hayward. PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines. Melanoma Res. 12:565-575, 2002.
115. Pollock, P. M., U. L. Harper, K. S. Hansen, L. M. Yudt, M. Stark, C. M. Robbins, T. Y. Moses, G. Hostetter, U. Wagner, J. Kakareka, G. Salem, T. Pohida, P. Heenan, P. Duray, O. Kallioniemi, N. K. Hayward, J. M. Trent, and P. S. Meltzer. High frequency of BRAF mutations in nevi. Nature Genet. 33:19-20, 2003.
116. Polsky, D., A. Z. Young, K. J. Busam, and R. M. Alani. The transcriptional repressor of p16/Ink4a, Id1, is up-regulated in early melanomas. Cancer Res. 61:6008-6011, 2001.
117. ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723, 1998.
118. Randerson-Moor, J. A., M. Harland, S. Williams, D. Cuthbert-Heavens, E. Sheridan, J. Aveyard, K. Sibley, L. Whitaker, M. Knowles, J. N. Bishop, and D. T. Bishop. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum. Mol. Genet. 10:55-62, 2001.
119. Rizos, H., S. Puig, C. Badenas, J. Malvehy, A. P. Darmanian, L. Jimenez, M. Mila, and R. F. Kefford. A melanoma-associated germline mutation in exon 1beta inactivates p14ARF. Oncogene 20:5543-5547, 2001 a.
120. Rizos, H., A. P. Darmanian, E. A. Holland, G. J. Mann, and R. F. Kefford. Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14ARF. J. Biol. Chem. 276:41424-41434, 2001 b.
121. Robertson, G. P., F. B. Furnari, M. E. Miele, M. J. Glendening, D. R. Welch, J. W. Fountain, T. G. Lugo, H. J. Huang, and W. K. Cavenee. In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proc. Natl. Acad. Sci. USA 95:9418-9423, 1998.
122. Robles, A. I., N. A. Bemmels, A. B. Foraker, and C. C. Harris. APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis. Cancer Res. 61:6660-6664, 2001.
123. Rocco, J. W., and D. Sidransky. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp. Cell Res. 264:42-55, 2001.
124. Rothhammer, T., J. C. Hahne, A. Florin, I. Poser, F. Soncin, N. Wernert, and A. K. Bosserhoff. The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma. Cell Mol. Life Sci. 61:118-128, 2004.
125. Ruas, M., and G. Peters. The p161NK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta 1378:F115-F177, 1998.
126. Rudolph, P., C. Schubert, S. Tamm, K. Heidorn, A. Hauschild, I. Michalska, S. Majewski, G. Krupp, S. Jablonska, and R. Parwaresch. Telomerase activity in melanocytic lesions: a potential marker of tumor biology. Am. J. Pathol. 156:1425-1432, 2000.
127. Sage, J., G. J. Mulligan, L. D. Attardi, A. Miller, S. Chen, B. Williams, Theodorou, and T. Jacks. Targeted disruption of the three Rb-related genes leads to loss of G1 control and immortalization. Genes Dev. 14:3037-3050, 2000.
128. Satyamoorthy, K., T. Bogenrieder, and M. Herlyn. No longer a molecular black box-new clues to apoptosis and drug resistance in melanoma. Trends Mol. Med. 7:191-194, 2001.
129. Sauroja, I., J. Smeds, T. Vlaykova, R. Kumar, L. Talve, M. Hahka-Kemppinen, K. Punnonen, C. T. Jansen, K. Hemminki, and S. Pyrhonen. Analysis of G(1)/S checkpoint regulators in metastatic melanoma. Genes Chromosomes Cancer 28:404-414, 2000.
130. Sauter, E. R., U. C. Yeo, A. von Stemm, W. Zhu, S. Litwin, D. S. Tichansky, G. Pistritto, M. Nesbit, D. Pinkel, M. Herlyn, and B. C. Bastian. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res. 62:3200-3206, 2002.
131. Scott, M. C., K. Wakamatsu, S. Ito, A. L. Kadekaro, N. Kobayashi, J. Groden, R. Kavanagh, T. Takakuwa, V. Virador, V. J. Hearing, and Z. A. Abdel-Malek. Human melanocortin 1 receptor variants, receptor function and melanocyte response to UV radiation. J. Cell Sci. 115:2349-2355, 2002.
132. Serrano, M., G. J. Hannon, and D. Beach. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707, 1993.
133. Serrano, M., H. W. Lee, L. Chin, C. Cordon-Cardo, D. Beach, and R. A. DePinho. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85:27-37, 1996.
134. Shahbazi, M., V. Pravica, N. Nasreen, H. Fakhoury, A. A. Fryer, R. C. Strange, P. E. Hutchinson, J. E. Osborne, J. T. Lear, A. G. Smith, and I. V. Hutchinson. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 359:397-401, 2002.
135. Sharpless, N. E., and R. A. DePinho. The INK4A/ARF locus and its two gene products. Curr. Opin. Genet. Dev. 9:22-30, 1999.
136. Sharpless, N. E., and R. A. DePinho. Telomeres, stem cells, senescence, and cancer. J. Clin. Invest. 113:160-168, 2004.
137. Arf predisposes mice to tumorigenesis. Nature 413:86-91, 2001.
138. Sherr, C. J. The INK4a/ARF network in tumour suppression. Nature Rev. Mol. Cell Biol. 2:731-737, 2001.
139. Smith, J. R., and O. M. Pereira-Smith. Replicative senescence: implications for in vivo aging and tumor suppression. Science 273:63-67, 1996.
140. Soengas, M. S., P. Capodieci, D. Polsky, J. Mora, M. Esteller, X. Opitz-Araya, R. McCombie, J. G. Herman, W. L. Gerald, Y. A. Lazebnik, C. Cordon-Cardo, and S. W. Lowe. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409:207-211, 2001.
141. Soufir, N., M. F. Avril, A. Chompret, F. Demenais, J. Bombled, A. Spatz, D. Stoppa-Lyonnet, J. Benard, and B. Bressac-de Paillerets. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum. Mol. Genet. 7:209-216, 1998.
142. Stambolic, V., A. Suzuki, J. L. de la Pompa, G. M. Brothers, C. Mirtsos, T. Sasaki, J. Ruland, J. M. Penninger, D. P. Siderovski, and T. W. Mak. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95:29-39, 1998.
143. Staunton, M. J., and E. F. Gaffney. Tumor type is a determinant of susceptibility to apoptosis. Am. J. Clin. Pathol. 103:300-307, 1995.
144. Straume, O., and L. A. Akslen. Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. Int. J. Cancer 74:535-539, 1997.
145. Straume, O., L. Sviland, and L. A. Akslen. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin. Cancer Res. 6:1845-1853, 2000.
146. Ink4a in melanocyte senescence and differentiation. J. Natl. Cancer Inst. 94:446-454, 2002.
147. Sviderskaya, E. V., V. C. Gray-Schopfer, S. P. Hill, N. P. Smit, T. J. Evans-Whipp, J. Bond, L. Hill, V. Bataille, G. Peters, D. Kipling, D. Wynford-Thomas, and D. C. Bennett. p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apopto-sis, and immortalization: possible implications for melanoma progression. J. Natl. Cancer Inst. 95:723-732, 2003.
148. Teng, D. H., R. Hu, H. Lin, T. Davis, D. Iliev, C. Frye, B. Swedlund, K. L. Hansen, V. L. Vinson, K. L. Gumpper, L. Ellis, A. El Naggar, M. Frazier, S. Jasser, L. A. Langford, J. Lee, G. B. Mills, M. A. Pershouse, R. E. Pollack, C. Tornos, P. Troncoso, W. K. Yung, G. Fujii, A. Berson, and P. A. Steck. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res. 57:5221-5225, 1997.
149. Tsao, H., X. Zhang, K. Fowlkes, and F. G. Haluska. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res. 60:1800-1804, 2000.
150. Tucker, M. A., and A. M. Goldstein. Melanoma etiology: where are we? Oncogene 22:3042-3052, 2003.
151. Valverde, P., E. Healy, I. Jackson, J. L. Rees, and A. J. Thody. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nature Genet. 11:328-330, 1995.
152. van't Veer, L. J., B. M. T. Burgering, R. Versteeg, A. J. M. Boot, D. J. Ruiter, S. Osanto, P. I. Schrier, and J. L. Bos. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol. Cell. Biol. 9:3114-3116, 1989.
153. Vaziri, H., and S. Benchimol. Alternative pathways for the extension of cellular life span: inactivation of p53/pRb and expression of telomerase. Oncogene 18:7676-7680, 1999.
154. Venkitaraman, A. R. A growing network of cancer-susceptibility genes. N. Engl. J. Med. 348:1917-1919, 2003.
155. Villa, R., C. D. Porta, M. Folini, M. G. Daidone, and N. Zaffaroni. Possible regulation of telomerase activity by transcription and alternative splicing of telomerase reverse transcriptase in human melanoma. J. Invest. Dermatol. 116:867-873, 2001.
156. Walker, G. J., and N. K. Hayward. Pathways to melanoma development: lessons from the mouse. J. Invest. Dermatol. 119:783-792, 2002.
157. Wehrle-Haller, B. The role of Kit-ligand in melanocyte development and epidermal homeostasis. Pigment Cell Res. 16:287-296, 2003.
158. Wei, Q., J. E. Lee, J. E. Gershenwald, M. I. Ross, P. F. Mansfield, S. S. Strom, L. E. Wang, Z. Guo, Y. Qiao, C. I. Amos, M. R. Spitz, and M. Duvic. Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma. J. Natl. Cancer Inst. 95:308-315, 2003.
159. ARF in replicative and induced senescence of human fibroblasts. Mol. Cell. Biol. 21:6748-6757, 2001.
160. Wellbrock, C., L. Ogilvie, D. Hedley, M. Karasarides, J. Martin, D. Niculescu-Duvaz, C. J. Springer, and R. Marais. V599EB-RAF is an oncogene in melanocytes. Cancer Res. 64:2338-2342, 2004.
161. Worm, J., C. Christensen, K. Gronbaek, E. Tulchinsky, and P. Guldberg. Genetic and epigenetic alterations of the APC gene in malignant melanoma. Oncogene 23:5215-5226, 2004.
162. Wu, H., V. Goel, and F. G. Haluska. PTEN signaling pathways in melanoma. Oncogene 22:3113-3122, 2003.
163. Wynford-Thomas, D. Cellular senescence and cancer. J. Pathol. 187:100-111, 1999.
164. Xiao, Z. X., J. Chen, A. J. Levine, N. Modjtahedi, J. Xing, W. R. Sellers, and D. M. Livingston. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375:694-698, 1995.
165. Yamada, K. M., and M. Araki. Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J. Cell Sci. 114:2375-2382, 2001.
166. Yamamura, K., S. Kamada, S. Ito, K. Nakagawa, M. Ichihashi, and Y. Tsujimoto. Accelerated disappearance of melanocytes in bcl-2-deficient mice. Cancer Res. 56:3546-3550, 1996.
167. Yazdi, A. S., G. Palmedo, M. J. Flaig, U. Puchta, A. Reckwerth, A. Rutten, T. Mentzel, H. Hugel, M. Hantschke, M. H. Schmid-Wendtner, H. Kutzner, and C. A. Sander. Mutations of the BRAF gene in benign and malignant melanocytic lesions. J. Invest. Dermatol. 121:1160-1162, 2003.
168. INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15:203-211, 1997.
169. INK4a binding domain of CDK4 in familial melanoma. Nature Genet. 12:97-99, 1996.